C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy

Change in SCVp and SCVi after 6 months of C-peptide therapy (n = 49, ▪) and placebo administration (n = 21, □) in the least affected half of the patients, i.e., those with SCVp >−2.5 SD at baseline. SCVi represents the fastest population of the axons in the nerve, whereas SCVp provides an estimate of the average conduction velocity. P values below the columns refers to within-group changes.